Spoke Chooses T IoT from T-Mobile and Deutsche Telekom to Pave the Way for Safer Cycling
13.7.2022 17:34:00 EEST | Business Wire | Press release
Today, T-Mobile (NASDAQ: TMUS) and Deutsche Telekom (NASDAQ: DTEGY) announced that Spoke, a mobility platform for safety, connectivity and rich rider experiences, will use T IoT to help bicyclists and motorists share the road more safely. T IoT, a comprehensive solution for global IoT connectivity, platform management and support, will power Spoke’s new hardware and software system that delivers near real-time information to bicyclists and motorists on the road, to help them reach their destination safely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712006196/en/
With T IoT, Spoke aims to improve awareness between bicyclists and motorists worldwide (Graphic: Business Wire)
According to the National Highway Traffic Safety Administration, 78 percent of bicycle accidents happen in urban areas where bicyclists ride near traffic. Spoke is on a journey to shrink those numbers by creating an ecosystem of IoT-connected sensors and cameras to provide bicyclists and motorists with highly accurate and timely alerts that will be delivered over LTE and 5G. This helps ensure that bicycles can “digitally” see cars, and more importantly, that cars can see bicycles.
Consider that there were nearly 50 million bicycles sold last year across the world. Then think about the millions of connected vehicles on roadways across the globe. Right now, the process of connecting vehicles to data requires the time-consuming, cumbersome process of enterprise negotiations with different network operators and IoT platforms. And bicyclists and motorists obviously don’t care how a safety notification is delivered or which jurisdiction they are in, as long as alerts are timely and actionable — because the outcome can oftentimes prevent property damage, injury, or ultimately save a life.
T IoT delivers network connectivity spanning the full range of technologies to support nearly every possible IoT scenario today, and tomorrow — including NB-IoT, LTE-M, LTE, and 5G — making it optimized to help deliver near real-time connectivity at scale, in 188 destinations worldwide.
“T IoT supports the low-latency speed and massive data required to connect Spoke’s global network of hardware and software on the road,” said Jarrett Wendt, CEO, Spoke. “As a result, Spoke will deliver much more than peace of mind for cyclists. It will deliver a world-class user experience with ride-enriching features made just for them — like traffic, navigation, ride and health information. T-Mobile and Deutsche Telekom’s leading innovation makes them the perfect teammate for Spoke’s solutions.”
“Spoke is exactly the kind of customer, innovation, and global application we had in mind when we launched T IoT earlier this year,” said Mishka Dehghan, Senior Vice President, Strategy, Product, and Solutions Engineering, T-Mobile Business Group. “Spoke is looking to leverage IoT and 5G for global good, and with T IoT, they will have one team and solution to manage all their connections around the world — to help the most vulnerable on our roadways by connecting them to the mobility ecosystem around them.”
“The future of our traffic system is based on a robust vehicle-to-everything (C-V2X) ecosystem provided through global cellular 5G connectivity. We are happy to support pioneers like Spoke and help building up a reliable connected system for mobility safety and rich rider experiences through our T IoT global footprint”, said Dennis Nikles, CEO of Deutsche Telekom IoT.
To learn more about T IoT from T-Mobile and Deutsche Telekom, go to: www.t-mobile.com/business/solutions/iot/T IoT-global
For more information about Spoke, visit: www.spokesafety.com
Qualifying service & devices required. Coverage not available in some areas.
About T-Mobile
T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712006196/en/
Contact information
Media Contacts
T-Mobile US, Inc. Media Relations
MediaRelations@t-mobile.com
Investor Relations Contact
T-Mobile US, Inc.
investor.relations@t-mobile.com
https://investor.t-mobile.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom